Resource Summary Report

Generated by FDI Lab - SciCrunch.org on Apr 28, 2025

BCBL-1

RRID:CVCL_0165
Type: Cell Line

Proper Citation

(RRID:CVCL_0165)

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0165

Proper Citation: (RRID:CVCL_0165)

Sex: Male

Defining Citation: PMID:8612236, PMID:9375005, PMID:9766492, PMID:15613351, PMID:17121789, PMID:17324269, PMID:19521981, PMID:19608668, PMID:21685375, PMID:28196595, PMID:31160637

Comments: Omics: Transcriptome analysis by RNAseq., Omics: Transcriptome analysis by microarray., Omics: Protein expression by reverse-phase protein arrays., Omics: H3K4me3 ChIP-seq epigenome analysis., Omics: H3K27me3 ChIP-seq epigenome analysis., Omics: Deep exome analysis., Omics: Array-based CGH., Karyotypic information: Has lost chromosome Y., Part of: MD Anderson Cell Lines Project., Part of: LL-100 blood cancer cell line panel.

Category: Cancer cell line

Name: BCBL-1

Synonyms: BCBL1, BCBL, Body Cavity Based Lymphoma-1

Cross References: BTO:BTO_0002727, EFO:EFO_0002048, MCCL:MCC:0000057, ArrayExpress:E-MTAB-7721, ArrayExpress:E-MTAB-7722, BEI_Resources:ARP-3233, BioSample:SAMN03473436, BioSamples:SAMEA365914, BioSamples:SAMEA365927, cancercelllines:CVCL_0165, Cosmic:1238078, Cosmic:1515185, Cosmic:1588560, DSMZ:ACC-683, DSMZCellDive:ACC-683, GEO:GSM33134, GEO:GSM38800, GEO:GSM38801, GEO:GSM634735, GEO:GSM710421, GEO:GSM710437, GEO:GSM1265856, GEO:GSM1265857, GEO:GSM1265858, GEO:GSM1265859,

GEO:GSM1265860, GEO:GSM1265868, GEO:GSM3150238, IARC_TP53:26980, Lonza:238, PRIDE:PXD012087, Progenetix:CVCL_0165, TOKU-E:4070, Wikidata:Q54795334

ID: CVCL_0165

Record Creation Time: 20250131T194511+0000

Record Last Update: 20250131T194944+0000

Ratings and Alerts

No rating or validation information has been found for BCBL-1.

No alerts have been found for BCBL-1.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 291 mentions in open access literature.

Listed below are recent publications. The full list is available at FDI Lab - SciCrunch.org.

Galaski J, et al. (2024) Fusobacterium nucleatum subsp. nucleatum RadD binds Siglec-7 and inhibits NK cell-mediated cancer cell killing. iScience, 27(6), 110157.

White MC, et al. (2024) Inhibition of NEK2 Promotes Chemosensitivity and Reduces KSHV-positive Primary Effusion Lymphoma Burden. Cancer research communications, 4(4), 1024.

Knickmann J, et al. (2024) A simple method for rapid cloning of complete herpesvirus genomes. Cell reports methods, 4(2), 100696.

Tuohinto K, et al. (2023) KSHV infection of endothelial precursor cells with lymphatic characteristics as a novel model for translational Kaposi's sarcoma studies. PLoS pathogens, 19(1), e1010753.

Pan Y, et al. (2023) The Poisson distribution model fits UMI-based single-cell RNA-sequencing data. BMC bioinformatics, 24(1), 256.

Liu Y, et al. (2023) Suppressing Kaposi's Sarcoma-Associated Herpesvirus Lytic Gene Expression and Replication by RNase P Ribozyme. Molecules (Basel, Switzerland), 28(8).

Kotzur R, et al. (2023) Eradication of CD48-positive tumors by selectively enhanced YTS cells harnessing the lncRNA NeST. iScience, 26(8), 107284.

Li X, et al. (2023) Suppression of KSHV lytic replication and primary effusion lymphoma by selective RNF5 inhibition. PLoS pathogens, 19(1), e1011103.

Lipka E, et al. (2023) NPP-669, a Novel Broad-Spectrum Antiviral Therapeutic with Excellent Cellular Uptake, Antiviral Potency, Oral Bioavailability, Preclinical Efficacy, and a Promising Safety Margin. Molecular pharmaceutics, 20(1), 370.

Chen J, et al. (2023) Role of Histamine and Related Signaling in Kaposi's Sarcoma-Associated Herpesvirus Pathogenesis and Oncogenesis. Viruses, 15(4).

Moore LN, et al. (2023) Bcl-xL is required to protect endothelial cells latently infected with KSHV from virus induced intrinsic apoptosis. PLoS pathogens, 19(5), e1011385.

Tsyklauri O, et al. (2023) Regulatory T cells suppress the formation of potent KLRK1 and IL-7R expressing effector CD8 T cells by limiting IL-2. eLife, 12.

Chen J, et al. (2023) Oncolytic strategy using new bifunctional HDACs/BRD4 inhibitors against virus-associated lymphomas. PLoS pathogens, 19(1), e1011089.

Tian X, et al. (2023) Genome-Wide CRISPR-Cas9 Screen Identifies SMCHD1 as a Restriction Factor for Herpesviruses. mBio, 14(2), e0054923.

Sakamoto T, et al. (2023) Application of the CDK9 inhibitor FIT-039 for the treatment of KSHV-associated malignancy. BMC cancer, 23(1), 71.

Majerciak V, et al. (2022) Genome-wide regulation of KSHV RNA splicing by viral RNA-binding protein ORF57. PLoS pathogens, 18(7), e1010311.

Huang Y, et al. (2022) Targeting Glycolysis in Alloreactive T Cells to Prevent Acute Graft-Versus-Host Disease While Preserving Graft-Versus-Leukemia Effect. Frontiers in immunology, 13, 751296.

Yeh WW, et al. (2022) SUMO Modification of Histone Demethylase KDM4A in Kaposi's Sarcoma-Associated Herpesvirus-Induced Primary Effusion Lymphoma. Journal of virology, 96(16), e0075522.

Benedetti R, et al. (2022) Concomitant Inhibition of IRE1?/XBP1 Axis of UPR and PARP: A Promising Therapeutic Approach against c-Myc and Gammaherpesvirus-Driven B-Cell Lymphomas. International journal of molecular sciences, 23(16).

Zhang H, et al. (2022) Mitochondrial protein, TBRG4, modulates KSHV and EBV reactivation from latency. PLoS pathogens, 18(11), e1010990.